BACKGROUND: Growing evidence suggests a cardioprotective role of omega-3 polyunsaturated fatty acids (PUFA). However, the exact mechanisms underlying the effects of omega-3 PUFA in humans have not yet been fully clarified. PURPOSE: We sought to evaluate omega-3 PUFA-mediated effects on adipokines in patients with stable coronary artery disease (CAD) undergoing elective percutaneous coronary intervention (PCI). METHODS: We conducted a prospective, double-blind, placebo-controlled, randomized study, in which adiponectin, leptin and resistin were determined at baseline, 3-5 days and 30 days during administration of omega-3 PUFA 1 g/day (n=20) or placebo (n=28). RESULTS: As compared to controls administration of omega-3 PUFA resulted in increase of adiponectin by 13.4% (P<0.0001), reduction of leptin by 22% (P<0.0001) and increase of adiponectin to leptin (A/L) ratio by 45.5% (P<0.0001) at 30 days, but not at 3-5 days. Compared with placebo adiponectin was 12.7% higher (P=0.0042), leptin was 16.7% lower (P<0.0001) and A/L ratio was 33.3% higher (P<0.0001) in the omega-3 PUFA group at 30 days. Resistin decreased similarly in both groups after 1 month, without intergroup differences (P=0.32). The multivariate model showed that the independent predictors of changes in adiponectin at 1 month (P<0.001) were: omega-3 PUFA treatment, baseline platelet count, total cholesterol and those in leptin (P<0.0001) were: omega-3 PUFA treatment and waist circumference. Independent predictors of A/L ratio changes (P<0.0001) were: assigned treatment, current smoking and hyperlipidemia. CONCLUSIONS: In high risk stable coronary patients after PCI omega-3 PUFA supplementation improves adipokine profile in circulating blood. This might be a novel, favourable mechanism of omega-3 PUFA action.
RCT Entities:
BACKGROUND: Growing evidence suggests a cardioprotective role of omega-3 polyunsaturated fatty acids (PUFA). However, the exact mechanisms underlying the effects of omega-3 PUFA in humans have not yet been fully clarified. PURPOSE: We sought to evaluate omega-3 PUFA-mediated effects on adipokines in patients with stable coronary artery disease (CAD) undergoing elective percutaneous coronary intervention (PCI). METHODS: We conducted a prospective, double-blind, placebo-controlled, randomized study, in which adiponectin, leptin and resistin were determined at baseline, 3-5 days and 30 days during administration of omega-3 PUFA 1 g/day (n=20) or placebo (n=28). RESULTS: As compared to controls administration of omega-3 PUFA resulted in increase of adiponectin by 13.4% (P<0.0001), reduction of leptin by 22% (P<0.0001) and increase of adiponectin to leptin (A/L) ratio by 45.5% (P<0.0001) at 30 days, but not at 3-5 days. Compared with placebo adiponectin was 12.7% higher (P=0.0042), leptin was 16.7% lower (P<0.0001) and A/L ratio was 33.3% higher (P<0.0001) in the omega-3 PUFA group at 30 days. Resistin decreased similarly in both groups after 1 month, without intergroup differences (P=0.32). The multivariate model showed that the independent predictors of changes in adiponectin at 1 month (P<0.001) were: omega-3 PUFA treatment, baseline platelet count, total cholesterol and those in leptin (P<0.0001) were: omega-3 PUFA treatment and waist circumference. Independent predictors of A/L ratio changes (P<0.0001) were: assigned treatment, current smoking and hyperlipidemia. CONCLUSIONS: In high risk stable coronary patients after PCI omega-3 PUFA supplementation improves adipokine profile in circulating blood. This might be a novel, favourable mechanism of omega-3 PUFA action.
Authors: Alan A Sneddon; Fotini Tsofliou; Claire L Fyfe; Ian Matheson; Diane M Jackson; Graham Horgan; Maria S Winzell; Klaus W J Wahle; Bo Ahren; Lynda M Williams Journal: Obesity (Silver Spring) Date: 2008-03-06 Impact factor: 5.002
Authors: Deborah C L Masquio; Aline de Piano; Priscila L Sanches; Flávia C Corgosinho; Raquel M S Campos; June Carnier; Patrícia L da Silva; Danielle A Caranti; Lian Tock; Lila M Oyama; Claudia M Oller do Nascimento; Marco T de Mello; Sergio Tufik; Ana R Dâmaso Journal: Clin Endocrinol (Oxf) Date: 2013-03-25 Impact factor: 3.478
Authors: E Guallar; A Aro; F J Jiménez; J M Martín-Moreno; I Salminen; P van't Veer; A F Kardinaal; J Gómez-Aracena; B C Martin; L Kohlmeier; J D Kark; V P Mazaev; J Ringstad; J Guillén; R A Riemersma; J K Huttunen; M Thamm; F J Kok Journal: Arterioscler Thromb Vasc Biol Date: 1999-04 Impact factor: 8.311
Authors: Katarzyna Mizia-Stec; Maciej Haberka; Magdalena Mizia; Artur Chmiel; Klaudia Gieszczyk; Bartosz Lasota; Joanna Janowska; Barbara Zahorska-Markiewicz; Zbigniew Gąsior Journal: Arch Med Sci Date: 2011-11-08 Impact factor: 3.318
Authors: Thor Munch-Andersen; Kaspar Sorensen; Niels-Jacob Aachmann-Andersen; Lise Aksglaede; Anders Juul; Jørn W Helge Journal: Int J Circumpolar Health Date: 2013-08-07 Impact factor: 1.228